Table 1. Characteristics of the subjects.

Group	Patient	Sex	Age	Diagnosis	F/U (mo)	Progression	Adjuvant
Glioma II*	1	M	28	A	5	Yes	RT, CTx
	2	M	39	ODG	1	N/A	No
	3	M	25	ODG	0	N/A	RT, CTx
	4	F	32	ODG	26	No	RT, CTx
	5	M	36	A	0	N/A	RT
Glioma III/IV (-)†	6	F	33	A-A	56	No	RT
	7	F	27	A-A	38	No	RT, CTx
	8	M	48	A-ODG	63	No	RT, CTx
	9	F	52	A-OA	23	Yes	RT
	10	M	35	A-ODG	31	No	RT
	11	F	32	A-ODG	23	No	RT, CTx
	12	M	51	A-OA	55	No	RT
	13	F	62	A-EPN	5	N/A	RT, CTx
	14	M	70	GBL	5	N/A	No
	15	M	41	GBL	1	N/A	RT, CTx
	16	M	51	GBL	15	No	RT, CTx
	17	M	67	GBL	0	N/A	No
Glioma III/IV (+)‡	18	M	37	A-ODG	61	No	RT, CTx
	19	F	43	A-A	57	No	RT, CTx
	20	F	36	A-OA	55	No	CTx
	21	F	40	A-EPN	55	No	CTx
	22	M	42	GBL	22	No	RT, CTx
	23	F	43	GBL	9	N/A	RT, CTx
	24	M	50	GBL	0	N/A	No
	25	F	51	GBL	16	No	RT, CTx
	26	F	45	GBL	0	N/A	No

^*WHO grade II gliomas, ^†WHO grade III or IV gliomas without HSIC, ^‡WHO grade III or IV gliomas with HSIC. A-, anaplastic; EPN, ependymoma; GBL, glioblastoma; OA, oligoastrocytoma; ODG, oligodendroglioma; FLAIR, fluid attenuated inversion recovery; HSIC, high signal change at internal capsule in FLAIR MR image; N/A, not available; RT, radiotherapy; CTx, chemotherapy; F/U, follow up